Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Guardant Health, Inc. operates as a biotechnology company. The Company provides sequencing and cell diagnostics services for the cancer patients. Guardant Health serves patients worldwide.
Website: guardanthealth.com



Growth: Good revenue growth rate 22.0%, there is slowdown compared to average historical growth rates 25.5%. The revenue growth dynamics is stable Site traffic for the last 3 months showed a change of +141.5%

Profitability: LTM EBITDA margin is negative, -92.7%. On average the margin is decreasing steadily. Gross margin is high, +152.3%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.27 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 59.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 12.8% higher than minimum and 88.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.8x by EV / Sales multiple

Key Financials (Download financials)

Ticker: GH
Share price, USD:  (+4.4%)18.12
year average price 27.47  


year start price 22.51 2023-05-01

max close price 39.97 2023-08-30

min close price 16.07 2024-04-19

current price 18.12 2024-04-29
Common stocks: 101 923 002

Dividend Yield:  0.0%
Last revenue growth (y/y):  22.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  25.5%
Historical growth of EBITDA:  0.0%
EV / Sales: 3.6x
Margin (EBITDA LTM / Revenue): -92.7%
Fundamental value created in LTM:
Market Cap ($m): 1 847
Net Debt ($m): 192
EV (Enterprise Value): 2 039
Price to Book: 11.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-22Seeking Alpha

Guardant Health: Shield Launch Could Drive Multiple Expansion

2024-02-22Seeking Alpha

Guardant Health, Inc. (GH) Q4 2023 Earnings Call Transcript

2024-02-22Zacks Investment Research

Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say

2024-02-22Zacks Investment Research

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

2024-02-22Zacks Investment Research

Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet

2024-02-15Zacks Investment Research

Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2024-02-02Zacks Investment Research

Down -12.91% in 4 Weeks, Here's Why Guardant Health (GH) Looks Ripe for a Turnaround

2023-12-20Market Watch

Guardant Health shares slide as colon cancer test is set for FDA advisory committee review

2023-11-06Seeking Alpha

Guardant Health, Inc. (GH) Q3 2023 Earnings Call Transcript

2023-10-11The Motley Fool

1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol GH GH GH GH GH GH
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-22 2023-11-06 2023-08-03 2023-05-09 2023-02-23 2022-11-03
acceptedDate 2024-02-22 17:23:38 2023-11-06 16:58:53 2023-08-03 17:02:11 2023-05-09 17:00:24 2023-02-23 17:00:52 2022-11-03 17:13:19
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 155M 143M 137M 129M 127M 117M
costOfRevenue -81M 58M 54M 53M 47M 40M
grossProfit 236M 85M 83M 76M 80M 77M
grossProfitRatio 1.523 0.597 0.607 0.588 0.629 0.655
researchAndDevelopmentExpenses 90M 94M 90M 93M 107M 100M
generalAndAdministrativeExpenses 38M 36M 42M 40M 38M 41M
sellingAndMarketingExpenses 79M 69M 71M 76M 81M 80M
sellingGeneralAndAdministrativeExpenses 117M 105M 113M 117M 119M 121M
otherExpenses 227M 17M 41M -2M 5M 0
operatingExpenses 434M 199M 203M 210M 226M 222M
costAndExpenses 353M 257M 257M 263M 273M 262M
interestIncome 14M 12M 7M 3M 2M 2M
interestExpense -5M 644 000 645 000 644 000 644 000 644 000
depreciationAndAmortization -60M 11M 48M 1M 7M -7M
ebitda -253M -74M -72M -133M -139M -151M
ebitdaratio -1.629 -0.517 -0.522 -1.031 -1.093 -1.290
operatingIncome -198M -114M -120M -134M -146M -145M
operatingIncomeRatio -1.274 -0.794 -0.872 -1.041 -1.152 -1.232
totalOtherIncomeExpensesNet 10M 17M 41M 762 000 7M -17M
incomeBeforeTax -188M -86M -72M -133M -139M -162M
incomeBeforeTaxRatio -1.210 -0.599 -0.527 -1.036 -1.098 -1.379
incomeTaxExpense -541 000 490 000 496 000 240 000 602 000 115 000
netIncome -187M -86M -73M -134M -140M -162M
netIncomeRatio -1.206 -0.602 -0.531 -1.037 -1.103 -1.380
eps -1.580 -0.730 -0.670 -1.300 -1.360 -1.580
epsdiluted -1.580 -0.730 -0.670 -1.300 -1.360 -1.580
weightedAverageShsOut 119M 118M 109M 103M 103M 102M
weightedAverageShsOutDil 119M 118M 109M 103M 103M 102M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol GH GH GH GH GH GH
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-22 2023-11-06 2023-08-03 2023-05-09 2023-02-23 2022-11-03
acceptedDate 2024-02-22 17:23:38 2023-11-06 16:58:53 2023-08-03 17:02:11 2023-05-09 17:00:24 2023-02-23 17:00:52 2022-11-03 17:13:19
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 1 134M 457M 271M 224M 142M 158M
shortTermInvestments 35M 697M 954M 713M 870M 800M
cashAndShortTermInvestments 1 169M 1 155M 1 225M 937M 1 011M 958M
netReceivables 89M 89M 86M 87M 97M 86M
inventory 62M 77M 61M 46M 52M 63M
otherCurrentAssets 28M 26M 26M 34M 32M 24M
totalCurrentAssets 1 347M 1 347M 1 398M 1 104M 1 192M 1 131M
propertyPlantEquipmentNet 303M 309M 321M 334M 342M 347M
goodwill 3M 3M 3M 3M 3M 3M
intangibleAssets 9M 10M 10M 11M 12M 12M
goodwillAndIntangibleAssets 12M 13M 14M 14M 15M 16M
longTermInvestments 150 000 24 000 0 0 0 157M
taxAssets 0 -24 000 0 0 0 0
otherNonCurrentAssets 124M 128M 108M 59M 61M 52M
totalNonCurrentAssets 439M 450M 442M 407M 418M 571M
otherAssets 0 0 0 0 0 0
totalAssets 1 786M 1 797M 1 840M 1 512M 1 610M 1 702M
accountPayables 52M 78M 80M 67M 176M 41M
shortTermDebt 28M 26M 25M 24M 22M 20M
taxPayables 0 0 0 0 0 4M
deferredRevenue 18M 21M 12M 14M 17M 13M
otherCurrentLiabilities 108M 101M 84M 100M -22M 100M
totalCurrentLiabilities 206M 227M 201M 204M 193M 175M
longTermDebt 1 140M 1 332M 1 337M 1 343M 1 347M 1 353M
deferredRevenueNonCurrent 0 3M 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 -3M 0 0 0 0
otherNonCurrentLiabilities 282M 10M 9M 9M 9M 1 285M
totalNonCurrentLiabilities 1 422M 1 342M 1 346M 1 352M 1 357M 1 360M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 186M 219M 198M 205M 210M 237M
totalLiabilities 1 628M 1 569M 1 547M 1 556M 1 550M 1 535M
preferredStock 0 0 0 0 0 0
commonStock 1000.000 1000.000 1000.000 1000.000 1000.000 1000.000
retainedEarnings -2 142M -1 955M -1 869M -1 796M -1 662M -1 522M
accumulatedOtherComprehensiveIncomeLoss -4M -6M -8M -12M -20M -27M
othertotalStockholdersEquity 2 304M 2 189M 2 170M 1 764M 1 742M 1 716M
totalStockholdersEquity 159M 228M 293M -45M 60M 167M
totalEquity 159M 228M 293M -45M 60M 167M
totalLiabilitiesAndStockholdersEquity 1 786M 1 797M 1 840M 1 512M 1 610M 1 702M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 786M 1 797M 1 840M 1 512M 1 610M 1 702M
totalInvestments 35M 697M 954M 713M 870M 956M
totalDebt 1 354M 1 358M 1 337M 1 343M 1 369M 1 373M
netDebt 220M 901M 1 066M 1 119M 1 228M 1 215M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol GH GH GH GH GH GH
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-22 2023-11-06 2023-08-03 2023-05-09 2023-02-23 2022-11-03
acceptedDate 2024-02-22 17:23:38 2023-11-06 16:58:53 2023-08-03 17:02:11 2023-05-09 17:00:24 2023-02-23 17:00:52 2022-11-03 17:13:19
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -187M -86M -73M -134M -140M -162M
depreciationAndAmortization 11M 11M 11M 10M 10M 10M
deferredIncomeTax 67M -24M -43M 0 0 0
stockBasedCompensation 24M 22M 22M 22M 24M 21M
changeInWorkingCapital 64M -8M -20M 18M 12M 27M
accountsReceivables 18 000 -2M -2M 12M -11M 9M
inventory 15M -17M -14M 5M 11M -3M
accountsPayables 62M 1M -3M 14M 43M 7M
otherWorkingCapital -13M 9M -2M -13M -31M 15M
otherNonCashItems -58M 8M 8M 8M 4M 26M
netCashProvidedByOperatingActivities -79M -78M -94M -74M -91M -78M
investmentsInPropertyPlantAndEquipment -4M -2M -7M -8M -10M -22M
acquisitionsNet 0 -263M 0 0 0 0
purchasesOfInvestments 0 -73M -499M -63M -76M 0
salesMaturitiesOfInvestments 666M 336M 265M 228M 157M 63M
otherInvestingActivites 2M 263M 0 0 0 0
netCashUsedForInvestingActivites 663M 261M -241M 157M 71M 41M
debtRepayment -37 000 -37 000 -19 000 -18 000 -18 000 -18 000
commonStockIssued 94M 8M 381M 157 000 3M 0
commonStockRepurchased 3M -3M 7M 0 9M 0
dividendsPaid -21M -5M -21M 0 0 0
otherFinancingActivites 15M 4M 17M -993 000 -10M -19M
netCashUsedProvidedByFinancingActivities 91M 4M 384M -854 000 2M -19M
effectOfForexChangesOnCash 1M -526 000 -1M -163 000 1M -529 000
netChangeInCash 676M 186M 47M 82M -175M -57M
cashAtEndOfPeriod 1 134M 457M 271M 224M -17M 159M
cashAtBeginningOfPeriod 457M 271M 224M 142M 159M 215M
operatingCashFlow -79M -78M -94M -74M -91M -78M
capitalExpenditure -4M -2M -7M -8M -10M -22M
freeCashFlow -83M -80M -101M -82M -101M -100M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-22 21:05 ET
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
2024-02-15 21:05 ET
Guardant Health to Participate in Upcoming Investor Conferences
2024-02-01 21:05 ET
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
2024-01-17 13:05 ET
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
2024-01-08 14:00 ET
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
2024-01-08 07:30 ET
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
2024-01-08 07:30 ET
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
2024-01-02 16:00 ET
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
2023-12-21 14:00 ET
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
2023-12-20 21:05 ET
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-19 21:05 ET
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
2023-12-04 10:00 ET
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
2023-11-30 13:05 ET
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
2023-11-15 21:05 ET
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-15 08:00 ET
Guardant Health to Appeal Federal District Court Verdict
2023-11-13 00:00 ET
Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea
2023-11-06 21:05 ET
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
2023-11-03 12:00 ET
Guardant Health to Participate in Upcoming November Investor Conferences
2023-10-31 12:05 ET
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
2023-10-23 07:45 ET
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
2023-10-16 20:05 ET
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
2023-09-06 12:05 ET
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
2023-09-05 12:05 ET
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
2023-09-01 19:46 ET
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
2023-08-31 20:05 ET
Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-17 20:05 ET
Guardant Health to Host Investor Day on September 7, 2023
2023-08-03 20:05 ET
Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
2023-08-01 20:05 ET
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
2023-07-20 12:05 ET
Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana
2023-07-12 20:05 ET
Guardant Health to Report Second Quarter 2023 Financial Results on August 3, 2023
2023-07-05 12:05 ET
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
2023-05-31 12:05 ET
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
2023-05-30 01:00 ET
Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers
2023-05-26 12:00 ET
Guardant Health to Participate in Upcoming June Investor Conferences
2023-05-23 02:03 ET
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
2023-05-22 20:23 ET
Guardant Health Announces Proposed Public Offering of Common Stock
2023-05-17 12:05 ET
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
2023-05-16 12:00 ET
Guardant Health Releases Inaugural ESG Report
2023-05-09 20:05 ET
Guardant Health Reports First Quarter 2023 Financial Results
2023-05-09 14:15 ET
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
2023-05-08 20:05 ET
Guardant Health Announces Additions to Leadership Team
2023-05-05 12:00 ET
Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023
2023-04-27 20:05 ET
Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference
2023-04-25 12:05 ET
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
2023-04-21 12:05 ET
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
2023-04-19 20:05 ET
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
2023-04-18 12:05 ET
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
2023-04-11 12:05 ET
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
2023-03-21 12:05 ET
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
2023-03-10 13:05 ET
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
2023-02-27 21:05 ET
Musa Tariq Joins Guardant Health Board of Directors
2023-02-23 21:05 ET
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
2023-02-17 13:00 ET
Guardant Health to Participate in Upcoming March Investor Conferences
2023-02-15 13:05 ET
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
2023-02-08 13:05 ET
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
2023-02-02 13:05 ET
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
2023-02-02 11:00 ET
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
2023-02-01 21:05 ET
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
2023-01-31 13:05 ET
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
2023-01-30 12:05 ET
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
2023-01-19 13:05 ET
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
2023-01-17 21:05 ET
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
2023-01-09 13:05 ET
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results
2022-12-28 13:00 ET
Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference
2022-12-21 13:05 ET
Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy
2022-12-15 21:16 ET
Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
2022-12-08 21:05 ET
Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer
2022-12-01 13:05 ET
Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients
2022-11-03 20:05 ET
Guardant Health Reports Third Quarter 2022 Financial Results
2022-10-10 20:05 ET
Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022
2022-09-09 20:30 ET
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
2022-09-06 12:05 ET
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
2022-08-31 12:05 ET
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
2022-08-29 20:05 ET
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
2022-08-15 12:05 ET
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
2022-08-12 12:05 ET
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
2022-08-08 20:05 ET
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference
2022-08-08 10:15 ET
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
2022-08-05 12:05 ET
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
2022-08-04 20:05 ET
Guardant Health Reports Second Quarter 2022 Financial Results
2022-08-02 12:05 ET
Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test
2022-07-13 20:05 ET
Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022
2022-07-07 12:05 ET
Steve E. Krognes Joins Guardant Health Board of Directors
2022-07-06 10:12 ET
Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China
2022-06-13 12:05 ET
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
2022-05-26 20:05 ET
Guardant Health to Participate in Upcoming June Investor Conferences
2022-05-25 07:01 ET
First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d’Hebron Institute of Oncology
2022-05-23 12:05 ET
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-05-21 07:01 ET
Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022
2022-05-05 20:05 ET
Guardant Health Reports First Quarter 2022 Financial Results
2022-05-02 12:05 ET
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults
2022-04-28 12:05 ET
Guardant Health to Participate in the BofA Securities 2022 Healthcare Conference
2022-04-13 20:05 ET
Guardant Health to Report First Quarter Financial Results on May 5, 2022
2022-04-11 19:30 ET
Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting
2022-04-04 12:05 ET
Guardant Health Announces Partnership with Epic to Streamline Access to Company’s Broad Portfolio of Cancer Tests
2022-03-17 12:05 ET
Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by Illumina
2022-03-14 20:05 ET
Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan
2022-03-09 13:05 ET
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at the American Association for Cancer Research Annual Meeting
2022-03-08 13:05 ET
Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test
2022-02-23 21:05 ET
Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook
2022-02-07 21:05 ET
Guardant Health to Participate in Upcoming Investor Conferences
2022-02-01 21:05 ET
Guardant Health to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
2022-01-19 13:05 ET
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
2022-01-18 13:05 ET
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
2022-01-07 22:15 ET
Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation
2021-12-29 13:05 ET
Guardant Health to Participate Virtually in the 40th Annual J.P. Morgan Healthcare Conference
2021-12-17 13:05 ET
Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer
2021-12-06 13:05 ET
Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360® Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium
2021-11-11 21:05 ET
Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer
2021-11-08 21:05 ET
Guardant Health to Participate in the 2021 Stifel Healthcare Conference
2021-11-04 20:05 ET
Guardant Health Reports Third Quarter 2021 Financial Results
2021-11-04 00:05 ET
Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom
2021-10-25 12:05 ET
Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer
2021-10-20 20:30 ET
Guardant Health Appoints Myrtle Potter to Its Board of Directors
2021-10-08 12:05 ET
Guardant Health to Report Third Quarter Financial Results on November 4, 2021
2021-10-05 12:05 ET
Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers
2021-09-15 08:00 ET
Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers
2021-09-07 12:05 ET
New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360® Liquid Biopsy Blood Test for Comprehensive Genomic Profiling in Advanced Lung Cancer
2021-09-02 20:05 ET
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
2021-08-06 20:15 ET
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit
2021-08-05 20:05 ET
Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors
2021-08-05 20:03 ET
Guardant Health Reports Second Quarter 2021 Financial Results
2021-08-03 16:06 ET
TwinStrand Biosciences Announces Filing of Patent Infringement Lawsuit Against Guardant Health
2021-07-20 12:10 ET
Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic
2021-07-19 13:30 ET
AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding Round
2021-07-13 12:05 ET
Guardant Health to Report Second Quarter Financial Results on August 5, 2021
2021-06-22 12:05 ET
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling
2021-06-19 00:23 ET
CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
2021-06-18 23:57 ET
CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
2021-06-08 12:05 ET
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
2021-06-04 13:10 ET
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer
2021-05-28 17:15 ET
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
2021-05-28 05:52 ET
Guardant Health Files Lawsuit Against Natera for Misleading Oncologists
2021-05-21 19:14 ET
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2021-05-20 12:05 ET
Guardant Health to Participate in Upcoming June Investor Conferences
2021-05-19 21:56 ET
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
2021-05-06 20:05 ET
Guardant Health Reports First Quarter 2021 Financial Results
2021-05-03 12:05 ET
Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer
2021-04-30 12:05 ET
Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
2021-04-29 12:05 ET
Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference
2021-04-27 12:05 ET
Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer
2021-04-12 20:05 ET
Guardant Health to Report First Quarter Financial Results on May 6, 2021
2021-04-10 12:35 ET
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers
2021-04-01 12:05 ET
Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage Cancer
2021-03-30 12:05 ET
Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360® CDx Test
2021-03-26 12:05 ET
Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer
2021-03-24 12:05 ET
Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer
2021-03-02 13:05 ET
Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers
2021-02-24 21:05 ET
Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021
2021-02-17 21:03 ET
Guardant Health to Participate in Upcoming Investor Conferences
2021-02-16 13:05 ET
Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer
2021-02-04 21:03 ET
Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
2021-01-27 13:05 ET
Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer with Similar Outcomes
2021-01-18 08:00 ET
Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe
2021-01-14 13:05 ET
Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal Cancer
2020-12-30 21:03 ET
Guardant Health to Participate in the 39th Annual J.P. Morgan Healthcare Conference
2020-12-11 22:00 ET
Guardant Health Names Michael Bell as New Chief Financial Officer
2020-12-07 13:05 ET
Guardant Health Presents Data at San Antonio Breast Cancer Symposium Demonstrating Utility of GuardantINFORM™ Real-World Platform in Metastatic Breast Cancer
2020-11-17 04:22 ET
Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering
2020-11-16 11:47 ET
Guardant Health, Inc. Announces Proposed Convertible Senior Notes Offering
2020-11-05 21:03 ET
Guardant Health Reports Third Quarter 2020 Financial Results
2020-10-16 20:05 ET
Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020
2020-10-15 20:05 ET
Guardant Health Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling Stockholder
2020-10-07 13:06 ET
Guardant Health Announces Pricing of Public Offering of Common Stock by Selling Stockholder
2020-10-06 20:54 ET
Guardant Health Announces Proposed Public Offering of Common Stock by Selling Stockholder
2020-10-05 20:05 ET
Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy
2020-09-01 20:03 ET
Guardant Health to Participate in Morgan Stanley 2020 Healthcare Conference
2020-08-24 12:05 ET
Guardant Health Receives FDA Emergency Use Authorization for its Guardant-19 Next Generation Sequencing-Based COVID-19 Test
2020-08-10 12:05 ET
Guardant Health to Participate in Upcoming August Investor Conferences
2020-08-07 18:25 ET
Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers
2020-08-06 20:03 ET
Guardant Health Reports Second Quarter 2020 Financial Results
2020-07-30 20:10 ET
Guardant Health Announces Collaboration with Radius Health to Develop Liquid Biopsy Companion Diagnostic for Elacestrant
2020-07-21 12:05 ET
Guardant Health Announces Webcast of Second Quarter Financial Results on August 6, 2020
2020-07-08 12:05 ET
Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic
2020-06-23 11:55 ET
Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug Development
2020-06-22 13:05 ET
Guardant Health Presents Data at AACR Virtual Annual Meeting II Showing Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal Cancer
2020-06-16 20:30 ET
Guardant Health Appoints Vijaya Gadde to its Board of Directors
2020-06-08 20:03 ET
Guardant Health Announces Full Exercise of Option and Closing of Public Offering
2020-06-02 02:32 ET
Guardant Health Announces Pricing of Upsized Public Offering
2020-06-01 20:37 ET
Guardant Health Announces Proposed Public Offering of Common Stock
2020-05-29 20:03 ET
Guardant Health to Participate in the William Blair 2020 Growth Stock Conference
2020-05-15 12:05 ET
Guardant Health Data at ASCO and AACR Demonstrates Growing Value of Liquid Biopsy for Precision Oncology in Advanced and Early Stage Cancer
2020-05-07 20:03 ET
Guardant Health Reports First Quarter 2020 Financial Results
2020-05-06 20:03 ET
Guardant Health to Participate in the BofA Securities 2020 Healthcare Conference
2020-05-05 12:05 ET
Guardant Health and Patient Advocacy Groups Join Forces to Raise Awareness of the Importance of Complete Biomarker Testing for Patients with Metastatic Non-Small Cell Lung Cancer
2020-05-02 14:35 ET
Guardant Health Presents Data at DDW Virtual Meeting Highlighting its Early Cancer Detection Program
2020-04-30 20:03 ET
Guardant Health Announces Webcast of First Quarter Financial Results on May 7, 2020
2020-04-09 12:05 ET
Study Shows Guardant360 Test Identifies Predictors of Response to PIK3CA Inhibitors in Women with HR+ Metastatic Breast Cancer
2020-02-24 21:03 ET
Guardant Health Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Outlook
2020-02-12 23:15 ET
Guardant Health to Participate in Upcoming Investor Conferences
2020-02-10 21:05 ET
Guardant Health to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020
2020-01-21 13:30 ET
Guardant Health Appoints High-Tech-Veteran Kumud Kalia Chief Information Officer
2020-01-13 13:30 ET
Guardant Health Announces Collaboration With Amgen to Develop a Global Liquid Biopsy Companion Diagnostic for AMG 510 KRAS G12C Inhibitor
2020-01-13 01:00 ET
Guardant Health and NRG Oncology Initiate Randomized Trial to Investigate Circulating Tumor DNA Guided Adjuvant Therapy in Stage II Colon Cancer
2019-12-30 21:05 ET
Guardant Health to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-19 18:45 ET
Guardant Health Receives Expanded Medicare Coverage for Guardant360 Across the Vast Majority of Solid Tumor Cancers
2019-12-13 13:15 ET
Large-Scale Study Shows Guardant360 Effectively Guides Precision Oncology Treatment in Metastatic Breast Cancer Patients
2019-12-11 13:15 ET
Study Shows Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker Testing
2019-11-07 21:03 ET
Guardant Health Reports Third Quarter 2019 Financial Results and Raises 2019 Revenue Guidance
2019-11-04 21:05 ET
Guardant Health to Report Third Quarter 2019 Financial Results on November 7, 2019
2019-10-23 20:03 ET
Guardant Health Initiates ECLIPSE Pivotal Study for its LUNAR-2 Blood Test for Colorectal Cancer Screening
2019-09-28 17:05 ET
Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy
2019-03-12 20:05 ET
Guardant Health Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Full Year 2019 Outlook
2019-03-12 01:58 ET
Guardant Health to Present at the 39th Annual Cowen Health Care Conference
2019-03-12 01:33 ET
Guardant Health to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019

SEC forms

Show financial reports only

SEC form 10
2024-02-22 17:23 ET
Guardant Health published news for 2023 q4
SEC form 8
2024-02-22 16:10 ET
Guardant Health published news for 2023 q4
SEC form 8
2024-02-22 16:10 ET
Guardant Health reported for 2023 q4
SEC form 10
2024-02-22 00:00 ET
Guardant Health published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Guardant Health published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Guardant Health published news for 2023 q4
SEC form 10
2023-11-06 16:58 ET
Guardant Health published news for 2023 q3
SEC form 8
2023-11-06 16:10 ET
Guardant Health reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Guardant Health published news for 2023 q3
SEC form 10
2023-08-03 17:02 ET
Guardant Health published news for 2023 q2
SEC form 6
2023-08-03 16:14 ET
Guardant Health reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Guardant Health published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Guardant Health published news for 2023 q2
SEC form 6
2023-08-01 16:15 ET
Guardant Health published news for 2023 q2
SEC form 6
2023-06-20 16:08 ET
Guardant Health published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Guardant Health published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Guardant Health reported for 2023 q1
SEC form 6
2023-04-10 16:58 ET
Guardant Health published news for 2023 q1
SEC form 6
2023-03-10 21:05 ET
Guardant Health published news for 2022 q4
SEC form 6
2023-03-07 17:09 ET
Guardant Health published news for 2022 q4
SEC form 6
2023-02-27 16:10 ET
Guardant Health published news for 2022 q4
SEC form 10
2023-02-23 17:00 ET
Guardant Health reported for 2022 q4
SEC form 6
2023-02-23 16:12 ET
Guardant Health published news for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Guardant Health reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Guardant Health reported for 2022 q4
SEC form 6
2023-01-09 08:08 ET
Guardant Health published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Guardant Health published news for 2022 q4
SEC form 6
2022-12-15 16:17 ET
Guardant Health published news for 2022 q3
SEC form 10
2022-11-03 17:13 ET
Guardant Health reported for 2022 q3
SEC form 6
2022-11-03 16:11 ET
Guardant Health published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Guardant Health reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Guardant Health reported for 2022 q3
SEC form 6
2022-08-12 16:13 ET
Guardant Health published news for 2022 q2
SEC form 6
2022-08-11 16:12 ET
Guardant Health published news for 2022 q2
SEC form 10
2022-08-04 17:03 ET
Guardant Health reported for 2022 q2
SEC form 6
2022-08-04 16:14 ET
Guardant Health published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Guardant Health reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Guardant Health reported for 2022 q2
SEC form 6
2022-07-11 17:03 ET
Guardant Health published news for 2022 q2
SEC form 6
2022-07-07 08:08 ET
Guardant Health published news for 2022 q2
SEC form 6
2022-06-21 07:01 ET
Guardant Health published news for 2022 q1
SEC form 6
2022-06-13 08:05 ET
Guardant Health published news for 2022 q1
SEC form 6
2022-05-05 18:01 ET
Guardant Health published news for 2022 q1
SEC form 10
2022-05-05 17:14 ET
Guardant Health reported for 2022 q1
SEC form 6
2022-05-05 16:20 ET
Guardant Health published news for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Guardant Health reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Guardant Health reported for 2022 q1
SEC form 6
2022-04-28 16:11 ET
Guardant Health published news for 2022 q1
SEC form 6
2022-02-28 17:14 ET
Guardant Health published news for 2021 q4
SEC form 10
2022-02-24 17:00 ET
Guardant Health published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Guardant Health published news for 2021 q4
SEC form 6
2022-02-23 16:11 ET
Guardant Health published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
Guardant Health published news for 2021 q4
SEC form 6
2022-01-07 17:15 ET
Guardant Health published news for 2021 q4
SEC form 10
2021-11-04 17:08 ET
Guardant Health published news for 2021 q3
SEC form 6
2021-11-04 16:17 ET
Guardant Health published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Guardant Health published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Guardant Health published news for 2021 q3
SEC form 6
2021-10-27 17:00 ET
Guardant Health published news for 2021 q3
SEC form 6
2021-10-20 16:30 ET
Guardant Health published news for 2021 q3
SEC form 6
2021-08-06 17:05 ET
Guardant Health published news for 2021 q2
SEC form 10
2021-08-05 16:29 ET
Guardant Health published news for 2021 q2
SEC form 6
2021-08-05 16:12 ET
Guardant Health published news for 2021 q2
SEC form 6
2021-08-05 16:09 ET
Guardant Health published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Guardant Health published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Guardant Health published news for 2021 q2
SEC form 6
2021-07-08 17:05 ET
Guardant Health published news for 2021 q2
SEC form 6
2021-06-21 16:06 ET
Guardant Health published news for 2021 q1
SEC form 6
2021-05-17 08:30 ET
Guardant Health published news for 2021 q1
SEC form 6
2021-05-13 19:39 ET
Guardant Health published news for 2021 q1
SEC form 10
2021-05-06 17:09 ET
Guardant Health published news for 2021 q1
SEC form 6
2021-05-06 16:17 ET
Guardant Health published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Guardant Health published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Guardant Health published news for 2021 q1
SEC form 6
2021-04-29 16:44 ET
Guardant Health published news for 2021 q1
SEC form 10
2021-02-25 16:36 ET
Guardant Health published news for 2020 q4
SEC form 6
2021-02-24 16:11 ET
Guardant Health published news for 2020 q4
SEC form 6
2021-01-11 10:40 ET
Guardant Health published news for 2020 q4
SEC form 6
2021-01-07 16:49 ET
Guardant Health published news for 2020 q4
SEC form 6
2021-01-07 16:01 ET
Guardant Health published news for 2020 q4
SEC form 6
2020-12-11 17:00 ET
Guardant Health published news for 2020 q3
SEC form 6
2020-11-19 21:43 ET
Guardant Health published news for 2020 q3
SEC form 6
2020-11-17 16:10 ET
Guardant Health published news for 2020 q3
SEC form 10
2020-11-05 16:27 ET
Guardant Health published news for 2020 q3
SEC form 6
2020-11-05 16:14 ET
Guardant Health published news for 2020 q3
SEC form 6
2020-10-09 20:25 ET
Guardant Health published news for 2020 q3
SEC form 6
2020-10-06 16:02 ET
Guardant Health published news for 2020 q3